{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:40:07Z","timestamp":1774982407325,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017065","name":"University of Michigan Medical Center Rogel Cancer Center","doi-asserted-by":"publisher","award":["P30CA046592"],"award-info":[{"award-number":["P30CA046592"]}],"id":[{"id":"10.13039\/100017065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.medj.2024.10.024","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:47:11Z","timestamp":1734518831000},"page":"100547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["BilT03: Phase 1b\/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":false,"given":"Vaibhav","family":"Sahai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent A.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce S.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heloisa P.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenivasa R.","family":"Chandana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oxana","family":"Crysler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandan","family":"Kumar-Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Enzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Dippman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Gunchick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark M.","family":"Zalupski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.10.024_bib1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.10.024_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4251\/wjgo.v12.i1.83","article-title":"Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers","volume":"12","author":"Mizrahi","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.medj.2024.10.024_bib3","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.10.024_bib4","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-\u03baB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.10.024_bib5","first-page":"967","article-title":"Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer","volume":"49","author":"Melichar","year":"2002","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.medj.2024.10.024_bib6","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.1016\/j.vaccine.2010.09.046","article-title":"Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model","volume":"28","author":"Kim","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.medj.2024.10.024_bib7","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell\u2013Dependent Antitumor Immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.10.024_bib8","doi-asserted-by":"crossref","first-page":"31411","DOI":"10.18632\/oncotarget.25830","article-title":"Topoisomerase I inhibitor, irinotecan, depletes regulatory T\u00a0cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies","volume":"9","author":"Iwai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2024.10.024_bib9","article-title":"Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer","volume":"6","author":"Liddell","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.medj.2024.10.024_bib10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.medj.2024.10.024_bib11","first-page":"S563","article-title":"53MO Nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC\u00a0\u2013 AIO-HEP-0116)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2024.10.024_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.medj.2024.10.024_bib13","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.34394","article-title":"A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01","volume":"128","author":"Sahai","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.medj.2024.10.024_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.10.024_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2024.10.024_bib16","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024004227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:01:26Z","timestamp":1762639286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024004227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666634024004227"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.024","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BilT03: Phase 1b\/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100547"}}